EcoR1 Capital’s Decoy Therapeutics DCOY Stock Holding History

EcoR1 Capital’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1	Closed	-$6.32M	–	35
2016 Q1	$6.32M	Hold	1	–	–	2.21%	21
2015 Q4	$9.9M	Hold	1	–	–	3.11%	14
2015 Q3	$11.2M	Hold	1	–	–	5.1%	8
2015 Q2	$15.6M	Hold	1	–	–	5.21%	7
2015 Q1	$15.8M	Buy	+1	New	+$15.5M	5.26%	9

Other funds holding DCOY

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

EcoR1 Capital's DCOY Position: Q2 2016 in Review

EcoR1 Capital sold out of Decoy Therapeutics (DCOY) in Q2 2016, closing a stake of 1 share — an estimated $6.32M sold.

EcoR1 Capital first reported a position in DCOY in Q1 2015 and held it in 5 quarters. The position peaked at $15.8M in Q1 2015. 4 funds tracked by Wall St. Rank hold DCOY as of Q2 2016.

EcoR1 Capital reported no remaining Decoy Therapeutics position as of Q2 2016 after selling out during the quarter.
EcoR1 Capital sold 1 Decoy Therapeutics share in Q2 2016, an estimated $6.32M.
EcoR1 Capital first reported a position in Decoy Therapeutics in Q1 2015 and held it in 5 quarters.
EcoR1 Capital's Decoy Therapeutics position peaked at $15.8M in Q1 2015.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2016.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.